Skip to Content


In the US, Ibrutinib (ibrutinib systemic) is a member of the drug class multikinase inhibitors and is used to treat Chronic Lymphocytic Leukemia, Graft-versus-host disease, Lymphoma, Mantle Cell Lymphoma, Non-Hodgkin's Lymphoma and Waldenström Macroglobulinemia.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Category

Antineoplastic agent: Tyrosine kinase inhibitor

Chemical Name

1-{(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl}prop-2-en-1-one (WHO)

Foreign Names

  • Ibrutinibum (Latin)
  • Ibrutinib (German)
  • Ibrutinib (French)
  • Ibrutinib (Spanish)

Generic Names

  • Ibrutinib (OS: USAN, JAN)
  • UNII-1X70OSD4VX (IS)
  • Ibrutinib (PH: JP XVI)

Brand Names

  • Imbruvica
    Catalent CTS, Israel; Janssen, Canada; Janssen, Denmark; Janssen, Ireland; Janssen, Norway; Janssen, New Zealand; Janssen, Sweden; Janssen, Slovakia; Janssen Cilag, Argentina; Janssen Pharmaceutica, Belgium; Janssen Pharmaceutical, Japan; Janssen-Cilag, Australia; Janssen-Cilag, Bosnia & Herzegowina; Janssen-Cilag, Brazil; Janssen-Cilag, Colombia; Janssen-Cilag, Czech Republic; Janssen-Cilag, Germany; Janssen-Cilag, Spain; Janssen-Cilag, United Kingdom; Janssen-Cilag, Greece; Janssen-Cilag, Lithuania; Janssen-Cilag, Peru; Janssen-Cilag, Poland; Janssen-Cilag International, Iceland; Janssen-Cilag International, Romania; Janssen-Cilag International NV, Netherlands; Janssen-Cilag International NV, Slovenia; Johnson & Johnson, Croatia (Hrvatska); Johnson & Johnson, Turkey; Pharmacyclics, China; Pharmacyclics, United States
    Janssen-Cilag, France
  • Imbruvica 140mg
    Janssen, Hungary; Janssen, Luxembourg; Janssen-Cilag, Switzerland; Janssen-Cilag Pharma, Austria


ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.